p53 status and the efficacy of cancer therapy in vivo. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) Science 266: 807-10 Optimising surveillance for relapse of Wilms' tumour. Lovvorn HN (2018) Lancet Oncol 19: 1006-1007 Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL (2001) J Clin Oncol 19: 1176-82 Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD (1990) J Clin Oncol 8: 1613-7 Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB, Coffey RJ (2005) J Clin Oncol 23: 9265-74 Combined small-cell and non-small-cell lung cancer. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH (1989) J Clin Oncol 7: 607-12 Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D (2019) J Clin Oncol 37: 1946-1955 [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD (2005) J Clin Oncol 23: 1136-43 When will melanoma vaccines be proven effective? Sosman JA, Weeraratna AT, Sondak VK (2004) J Clin Oncol 22: 387-9 Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. Pierce JP, Patterson RE, Senger CM, Flatt SW, Caan BJ, Natarajan L, Nechuta SJ, Poole EM, Shu XO, Chen WY (2014) J Natl Cancer Inst 106: djt359 Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) J Natl Cancer Inst 104: 1264; author reply 1266-8 Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Hainsworth JD, Grosh WW, Burnett LS, Jones HW, Wolff SN, Greco FA (1988) Ann Intern Med 108: 165-70 Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, Masuzaki R, Goto T, Hamamura K, Kanai F, Yoshida H, Kawabe T, Omata M (2009) Gut 58: 839-44 ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012 (2013) Eur Urol 63: 4-15 ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK (2014) Eur Urol 66: 77-84 Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84. Rathmell WK, Brooks SA, Parker JS, Nielsen ME (2014) Eur Urol 66: e92 Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, Tateishi R, Masuzaki R, Enooku K, Shiina S, Sato T, Obi S, Hoshino T, Nagatomo R, Okubo S, Yokota H, Koike K, Yatomi Y, Ikeda H (2012) J Hepatol 57: 330-6 SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE (2003) Cancer Res 63: 4009-16 A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL (2011) Clin Cancer Res 17: 2024-34 Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS (1999) Clin Cancer Res 5: 3956-62 Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS (2004) Clin Cancer Res 10: 136-43 Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA (2008) Clin Cancer Res 14: 7790-7 Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K (2012) Am J Gastroenterol 107: 569-77; quiz 578 A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh YC, Miller LL (2001) Ann Oncol 12: 1575-80 Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, Guarneri V (2019) Ann Oncol 30: 418-423 Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Song W, Hwang Y, Youngblood VM, Cook RS, Balko JM, Chen J, Brantley-Sieders DM (2017) Oncogene 36: 5620-5630 Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study. Jacobs ET, Thomson CA, Flatt SW, Al-Delaimy WK, Hibler EA, Jones LA, Leroy EC, Newman VA, Parker BA, Rock CL, Pierce JP (2011) Am J Clin Nutr 93: 108-17 Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, Flatt SW, Zheng Y, Zheng W, Pierce JP, Shu XO (2012) Am J Clin Nutr 96: 123-32 Recent advances in the treatment and outcome of locally advanced rectal cancer. Vauthey JN, Marsh RW, Zlotecki RA, Abdalla EK, Solorzano CC, Bray EJ, Freeman ME, Lauwers GY, Kubilis PS, Mendenhall WM, Copeland EM (1999) Ann Surg 229: 745-52; discussion 752-4 A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Nechuta S, Chen WY, Cai H, Poole EM, Kwan ML, Flatt SW, Patterson RE, Pierce JP, Caan BJ, Ou Shu X (2016) Int J Cancer 138: 2088-97 Semi-supervised learning improves gene expression-based prediction of cancer recurrence. Shi M, Zhang B (2011) Bioinformatics 27: 3017-23 Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Tsiatis AC, Herceg ME, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Cates JM (2009) Mod Pathol 22: 1432-8 A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA (2001) Cancer 92: 279-86 Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA (1995) Cancer 76: 1197-200 The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) Cancer 103: 2481-4 Upper tract transitional cell carcinoma: finding a way forward. Clark PE (2007) Cancer 110: 1648-9 Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG (2003) Cancer 98: 955-61 Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA (2008) Cancer 113: 186-92 Thymoma. A retrospective study of 87 cases. Park HS, Shin DM, Lee JS, Komaki R, Pollack A, Putnam JB, Cox JD, Hong WK (1994) Cancer 73: 2491-8 Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Parl FF, Schmidt BP, Dupont WD, Wagner RK (1984) Cancer 54: 2237-42
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.